Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Inclusion Criteria:

Diagnosis of metastatic castration-resistant prostate cancer with disease progression despite castrate levels of testosterone
Have radiographic or biochemical evidence of progression as determined by Investigator per standard criteria
Have no known active or symptomatic central nervous system (CNS) disease

Prior therapy with abiraterone required and:

For Phase 1b only: up to 2 prior taxane-based chemotherapy regimens allowed for castration-resistant disease
For Phase 2 only: Patients must not have received prior taxane-based chemotherapy for castrate-resistant disease or prior treatment with CDK inhibitors
Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2
Adequate bone marrow and organ function
Eligible to receive enzalutamide
Life expectancy of > 6 months

Exclusion Criteria:

History of seizure or any condition that may predispose to seizure (prior cortical stroke or significant brain trauma)
Have received chemotherapy, hormonal therapy (with the exception of ongoing LHRH analogs) radiation, or biological anti-cancer therapy within 14 days prior to first dose of NUV-422 and enzalutamide
Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days (or < 5 half-lives) for myelosuppressive agent prior to the first dose of NUV-422 and enzalutamide

Requires medications that are known to be strong inducers and /or inhibitors of CYP3A4/5 enzymes, except enzalutamide

For Phase 1b only: Requires medications that are known to be moderate inducers and /or inhibitors of CYP3A4/5 enzymes, except enzalutamide
Prior therapy with enzalutamide, apalutamide, darolutamide, or investigational androgen receptor inhibitors
Known allergy or hypersensitivity to enzalutamide